{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:32:04Z","timestamp":1790937124071,"version":"4.1.0"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We have developed a therapeutic for the treatment of anthrax using an affinity-enhanced monoclonal antibody (ETI-204) to protective antigen (PA), which is the central cell-binding component of the anthrax exotoxins. ETI-204 administered preexposure by a single intravenous injection of a dose of between 2.5 and 10 mg per animal significantly protected rabbits from a lethal aerosolized anthrax spore challenge (\u223c60 to 450 times the 50% lethal dose of\n                    <jats:italic>Bacillus anthracis<\/jats:italic>\n                    Ames). Against a similar challenge, ETI-204 administered intramuscularly at a 20-mg dose per animal completely protected rabbits from death (100% survival). In the postexposure setting, intravenous administration of ETI-204 provided protection 24 h (8 of 10) and 36 h (5 of 10) after spore challenge. Administration at 48 h postchallenge, when 3 of 10 animals had already succumbed to anthrax infection, resulted in the survival of 3 of 7 animals (43%) for the duration of the study (28 days). Importantly, surviving ETI-204-treated animals were free of bacteremia by day 10 and remained so until the end of the studies. Only 11 of 51 ETI-204-treated rabbits had positive lung cultures at the end of the studies. Also, rabbits that were protected from inhalational anthrax by administration of ETI-204 developed significant titers of PA-specific antibodies. Presently, the sole therapeutic regimen available to treat infection by inhalation of\n                    <jats:italic>B. anthracis<\/jats:italic>\n                    spores is a 60-day course of antibiotics that is effective only if administered prior to or shortly after exposure. Based upon results reported here, ETI-204 is an effective therapy for prevention and treatment of inhalational anthrax.\n                  <\/jats:p>","DOI":"10.1128\/iai.73.2.795-802.2005","type":"journal-article","created":{"date-parts":[[2005,1,20]],"date-time":"2005-01-20T21:03:07Z","timestamp":1106254987000},"page":"795-802","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":109,"title":["A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized\n                    <i>Bacillus anthracis<\/i>\n                    Spore Challenge"],"prefix":"10.1128","volume":"73","author":[{"given":"Nehal","family":"Mohamed","sequence":"first","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Clagett","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jones","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pincus","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"D'Alia","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nardone","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Babin","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Spitalny","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Casey","sequence":"additional","affiliation":[{"name":"Elusys Therapeutics Inc., Pine Brook, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00197-9"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/n35101999"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5364.734"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.10.3381-3386.1991"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00021-4"},{"key":"e_1_3_2_8_2","first-page":"2340","volume":"68","year":"2003","unstructured":"Food and Drug Administration. 2003. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Code Fed. Regul.68:2340-2341.","journal-title":"Code Fed. Regul."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)38364-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.1.245-252.1993"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(89)90397-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1735"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)80112-6"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020353"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.21.10277"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.2.544-550.2002"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.10.3162"},{"key":"e_1_3_2_19_2","first-page":"111","year":"1988","unstructured":"Leppla, S. H., A. M. Friedlander, and E. M. Cora. 1988. Proteolytic activation of anthrax toxin bound to cellular receptors, p. 111-112. In F. J. Fehenbach, J. E. Alouf, P. Falmagne, W. Goebel, J. Jeljaszewicz, D. Jurgens, and R. Rappuoli (ed.), Bacterial protein toxins. Gustav Fischer, New York, N.Y.","journal-title":"Bacterial protein toxins"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.7.1807-1813.1988"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.58.6.1606-1613.1990"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.12.5171-5175.1997"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.07.004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210321200"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0602-597"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32036-7"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1995.tb02375.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.647"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052160199"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.47.1.306-310.1985"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710432"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/385833a0"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00234-1"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2888-2893.2001"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0431098100"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.7.3447-3448.1998"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.4.1853-1859.1999"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2672.1999.00893.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-147-6-1677"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-51-10-821"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(88)90015-0"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M401292200"},{"key":"e_1_3_2_43_2","first-page":"982","volume":"122","year":"1998","unstructured":"Zaucha, G. M., L. M. Pitt, J. Estep, B. E. Ivins, and A. M. Friedlander. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med.122:982-992.","journal-title":"Arch. Pathol. Lab. Med."}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.73.2.795-802.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.73.2.795-802.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:40:26Z","timestamp":1646440826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.73.2.795-802.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1128\/IAI.73.2.795-802.2005"],"URL":"https:\/\/doi.org\/10.1128\/iai.73.2.795-802.2005","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"2004-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}